Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI

• Published in: Journal of Alzheimer's disease Vol. 51; no. 1; p. 227
• Main Authors: Wang, Hui-Fu, Tan, Lan, Cao, Lei, Zhu, Xi-Chen, Jiang, Teng, Tan, Meng-Shan, Liu, Ying, Wang, Chong, Tsai, Richard M, Jia, Jian-Ping, Yu, Jin-Tai
• Format: Journal Article
• Language: English
• Published: Netherlands 01-01-2016
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - physiopathology; Amyloid Precursor Protein Secretases - cerebrospinal fluid; Aspartic Acid Endopeptidases - cerebrospinal fluid; Cognitive Dysfunction - diagnostic imaging; Databases, Factual - statistics & numerical data; Disease Progression; Female; Humans; Longitudinal Studies; Male; Multicenter Studies as Topic; Neuroimaging; Psychiatric Status Rating Scales - standards; tau Proteins - cerebrospinal fluid; diagnostic markers; Alzheimer’s disease neuroimaging Initiative; Alzheimer’s disease; progression markers; international working group-2 criteria
• ISSN: 1875-8908
• DOI: 10.3233/JAD-150824

The International Working Group (IWG) recently proposed the revised diagnostic criteria for Alzheimer's disease (AD) to define and refine several types of AD, and to reclassify AD-related biomarkers into diagnostic and progression markers, but its performance is not known.
This study was designed to describe the application of the revised IWG criteria in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, and to ascertain whether diagnostic and progression markers show significant differences in their relationships to AD severity and progression.
Based on the requirements of the refined criteria, 857 ADNI subjects with memory evaluation and at least one pathophysiological marker (CSF or amyloid imaging biomarkers) were eligible and reclassified in this study, and we calculated the associations of diagnostic (CSF and amyloid PET) and progression markers (MRI and fluorodeoxyglucose-PET) with AD severity and progression respectively.
The majority (84.2% ) of ADNI AD group (n = 117) and 173 MCI (37.4% ) subjects in ADNI met the definition of typical AD; and 105 cognitively normal (41.0% ) individuals were diagnosed as asymptomatic AD. Furthermore, diagnostic and progression markers showed significant differences when correlated to AD severity and progression.
A large proportion of AD dementia subjects were categorized as typical AD, and the revised criteria could identify typical AD from MCI status as well as asymptomatic AD at the asymptomatic stage. Moreover, the significant differences between diagnostic and progression markers further supported the new biomarkers categorization in the refined criteria.